Harnessing autophagy for adoptive T-cell therapy

Immunotherapy

Volumn 4, Issue 1, 2012, Pages 1-4

  Amarnath, Shoba ^a   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

autophagy; immunology; rapamycin; Th1; Th2; transplantation; tumor

Indexed keywords

BECLIN 1; CHAPERONE; CYTOKINE; CYTOPLASM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; RAPAMYCIN;

AUTOPHAGOSOME; AUTOPHAGY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ENERGY; CELL MATURATION; CELL STRESS; CELL SURVIVAL; CELL THERAPY; ELECTRON MICROSCOPY; EX VIVO STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; AUTOPHAGY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 83655182357     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.144     Document Type: Review

References (26)

1. Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J. Clin. Oncol. 29(14), 1855-1863 (2011).
2. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY ESO 1. J. Clin. Oncol. 29(7), 917-924 (2011).
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
4. 4+ T cells expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8(1), 47-53 (2002). (Pubitemid 34101728)
5. Heslop HE, Slobod KS, Pule, MA et al. Long term outcome of EBV specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925-935 (2010).
6. 4+ T cells. Science 327(5969), 1098-1102 (2010).
7. 8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3), 808-814 (2011).
8. Kundu M, Thompson CB. Autophagy: basic principles and relevance to disease. Annu. Rev. Pathol. 3, 427-455 (2008).
9. Walsh CM, Edinger AL. The complex interplay between autophagy, apoptosis, and necrotic signals promotes T cell homeostasis. Immunol. Rev. 236, 95-109 (2010).
10. 4+ T cell immunity and tolerance. Cell Death Differ. 16(1), 79-86 (2009).
11. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162(5), 2775-2784 (1999). (Pubitemid 29309302)
12. Amarnath S, Flomerfelt FA, Costanzo CM et al. Rapamycin generates antiapoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy 6(4), 523-541 (2010).
13. Colell A, Ricci JE, Tait S et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 129(5), 983-997 (2007). (Pubitemid 46813151)
14. Fan QW, Cheng C, Hackett C et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 3(147), RA81 (2010).
15. Parkhitko A, Myachina F, Morrison TA et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc. Natl Acad. Sci. USA 108(30), 12455-12460 (2011).
16. Jung U, Foley JE, Erdmann AA et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol. Blood Marrow Transplant. 12(9), 905-918 (2006).
17. Finlay D, Cantrell D. Phosphoinositide 3 kinase and the mammalian target of rapamycin pathways control T cell migration. Ann. NY Acad. Sci. 1183, 149-157 (2010).
18. 8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
19. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33(3), 301-311 (2010).
20. 3+ regulatory T cells. Blood 105(12), 4743-4748 (2005). (Pubitemid 40807298)
21. 8+, Tc1/Tc2 populations in murine GVL: Type 1 cells generate GVL and type 2 cells abrogate GVL. Biol. Blood Marrow Transplant. 2(3), 118-125 (1996). (Pubitemid 126488208)
22. Foley JE, Jung U, Miera A et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL 4-dependent mechanism. J. Immunol. 175(9), 5732-5743 (2005). (Pubitemid 41508056)
23. Mariotti J, Foley J, Jung U et al. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J. Immunol. 180(1), 89-105 (2008).
24. Amarnath S, Chen H, Foley JE et al. Host-based Th2 cell therapy for prolongation of cardiac allograft viability. PLoS ONE 6(4), E18885 (2011).
25. Mossoba ME, Mariotti J, Yan XY et al. T rapa cell clinical products contain a balance of minimally differentiated Th2/Th1 effector cells depleted of Treg cells. Blood 116(21), 158-159 (2010).
26. Fowler DH, Mossoba ME, Schuver BB et al. Adoptive transfer of Treg depleted donor Th1 and Th2 cells safely accelerates alloengraftment after low intensity chemotherapy. Blood 116(21), 230-231 (2010).